Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE: 300573)

Shenyang Xingqi Pharmaceutical Co.,Ltd. Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	1,774	1,440	1,227	1,024	683.22	538.66
Other Revenue	27.86	27.86	23.2	3.6	5.46	3.78
Revenue	1,802	1,468	1,250	1,028	688.68	542.43
Revenue Growth (YoY)	33.44%	17.42%	21.59%	49.26%	26.96%	25.80%
Cost of Revenue	403.79	340.36	270.08	229.01	187.87	147.18
Gross Profit	1,398	1,127	979.78	798.91	500.81	395.26
Selling, General & Admin	803.84	689.8	595.39	456.54	321.34	292.04
Research & Development	185.23	167.3	145.61	88.45	63.19	53.97
Other Operating Expenses	17.36	7.16	6.66	13.8	3.14	9.53
Operating Expenses	1,008	867.29	748.58	558.6	388.71	357.77
Operating Income	389.84	259.93	231.2	240.31	112.1	37.49
Interest Expense	-4.69	-1.44	-0.94	-5.99	-5.94	-4.46
Interest & Investment Income	6.74	7.91	9.93	3.98	0.22	0.15
Currency Exchange Gain (Loss)	0.2	0.2	-0.09	-0.13	-0.02	0.01
Other Non Operating Income (Expenses)	7.61	-1.15	-19.31	-1.05	-3.74	-0.59
EBT Excluding Unusual Items	399.7	265.45	220.79	237.12	102.62	32.6
Gain (Loss) on Sale of Assets	0.1	-0.04	0.42	5.16	-0.08	0.01
Asset Writedown	-0.34	-	-0	-0	-	-
Other Unusual Items	0.73	-0.42	12.51	1.26	-	3.2
Pretax Income	400.16	264.99	233.72	243.54	102.54	35.82
Income Tax Expense	51.69	24.96	22.03	34.43	9.08	6.31
Earnings From Continuing Operations	348.47	240.04	211.68	209.11	93.46	29.51
Minority Interest in Earnings	-	-	-	-14.41	-5.48	6.38
Net Income	348.47	240.04	211.68	194.7	87.98	35.89
Net Income to Common	348.47	240.04	211.68	194.7	87.98	35.89
Net Income Growth	82.27%	13.39%	8.72%	121.31%	145.11%	162.79%
Shares Outstanding (Basic)	174	174	172	160	158	156
Shares Outstanding (Diluted)	174	174	172	160	161	156
Shares Change (YoY)	1.04%	1.06%	7.46%	-0.31%	2.88%	-0.77%
EPS (Basic)	2.00	1.38	1.23	1.22	0.56	0.23
EPS (Diluted)	2.00	1.38	1.23	1.21	0.55	0.23
EPS Growth	80.40%	12.21%	1.18%	120.42%	139.94%	164.82%
Free Cash Flow	269.7	55.61	-12.96	211.9	14.01	4.11
Free Cash Flow Per Share	1.55	0.32	-0.08	1.32	0.09	0.03
Dividend Per Share	2.633	2.643	0.765	0.332	0.128	0.064
Dividend Growth	158.01%	245.34%	130.79%	159.87%	100.00%	-50.00%
Gross Margin	77.59%	76.81%	78.39%	77.72%	72.72%	72.87%
Operating Margin	21.63%	17.71%	18.50%	23.38%	16.28%	6.91%
Profit Margin	19.34%	16.36%	16.94%	18.94%	12.77%	6.62%
Free Cash Flow Margin	14.97%	3.79%	-1.04%	20.61%	2.03%	0.76%
EBITDA	476.54	337.77	297.23	297.55	157.61	78.05
EBITDA Margin	26.45%	23.02%	23.78%	28.95%	22.89%	14.39%
D&A For EBITDA	86.71	77.85	66.03	57.24	45.51	40.56
EBIT	389.84	259.93	231.2	240.31	112.1	37.49
EBIT Margin	21.63%	17.71%	18.50%	23.38%	16.28%	6.91%
Effective Tax Rate	12.92%	9.42%	9.43%	14.14%	8.86%	17.61%
Revenue as Reported	1,802	1,468	1,250	1,028	688.68	542.43
Advertising Expenses	-	13.81	13	5.22	6.89	5.14

Source: S&P Capital IQ. Standard template. Financial Sources.